aTyr Pharma, Inc. (ATYR)

NCM – Real Time Price. Currency in USD

0.53

-0.03 (-5.75%)

At close: Jun 26, 2026, 4:00 PM EDT

0.56

+0.03 (5.36%)

After-hours: Jun 26, 2026, 7:23 PM EDT

15.05.2026

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.

13.05.2026

aTyr Pharma to Participate in Upcoming Investor Conferences

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in May and June 2026. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Location: New York, NYFormat: 1x1 Investor Meetings Conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 3:45pm ETLocation: New York, NYFormat: Fireside ChatSpeaker: Sanjay S.

12.05.2026

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript

12.05.2026

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma NASDAQ: ATYR said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.

11.05.2026

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.

05.03.2026

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026.

20.02.2026

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr's common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on February 17, 2026, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.

Videos

No Data

There is no data to display

Press releases

15.05.2026

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

11.05.2026

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

05.03.2026

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

20.02.2026

aTyr Pharma, Inc. (ATYR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

aTyr Pharma, Inc. (ATYR)

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma to Participate in Upcoming Investor Conferences

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma to Participate in Upcoming Investor Conferences

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

aTyr Pharma, Inc. (ATYR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

aTyr Pharma, Inc. (ATYR)

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma to Participate in Upcoming Investor Conferences

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma to Participate in Upcoming Investor Conferences

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Videos

No Data

Press releases

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)